East Montgomery Times

Scientists at Fox Chase Cancer Center have published a comprehensive review celebrating the 20th anniversary of the discovery of histone lysine demethylases (KDMs), a crucial development in the understanding of cancer and other diseases. The paper, appearing in the journal Cell, records the journey of KDM research over the past two decades and outlines potential future directions for research.

KDMs were first documented in 2004, revealing new insights into the genetic mechanisms underlying cancer. The review serves as a comprehensive summary of KDM research, containing around 400 citations and is described as a “one-stop shop” for researchers in the field, according to the study’s lead author and Fox Chase Director.

The review notes key breakthroughs such as the discovery of the enzyme lysine specific demethylase 1 (LSD1), confirming that demethylation is possible. This finding catalyzed significant growth in the field of epigenetics, as explained by a coauthor of the original study who has continued to study KDMs.

The current state of research indicates a need for additional work to understand how KDMs can be targeted therapeutically. Despite two KDMs being considered as cancer therapies, the author stresses further research is necessary to explore KDMs as biomarkers and potential therapeutic targets. He emphasized there is still much to be explored within KDM functions that could present new opportunities.

Whetstine, reflecting on past achievements, expressed optimism about future discoveries in KDM research. He is hopeful that their review will inspire the next generation of scientists to explore new areas within this field.

The paper, “20 Years of Histone Lysine Demethylases: From Discovery to the Clinic and Beyond,” documents these findings and ongoing challenges in KDM research.